Comments
Drug maker Lupin has received final approval from the US health regulator to market a generic version of UCB’s Keppra Oral Solution, an anti-epilepsy drug, in the American market.
The company’s subsidiary, Lupin Pharmaceuticals Inc, has received final approval for its Levetiracetam Oral Solution in the strength of 100mg/ml from US Food and Drug Administration (USFDA), Lupin said in a statement.
“Commercial shipment of the product shall commence shortly,” it added.
According to IMS Health sales data for the 12 months ended June 2011, Keppra Oral Solution 100 mg/mL had annual sales of nearly $63 million in the US market.
Last month, the company had received USFDA’s nod to sell a generic version of UCB’s Keppra XR tablets.
The company had received the approval to sell the tablets in the strengths of 500 mg and 750 mg. According to IMS Health sales data, Keppra XR tablets had annual sales of nearly $161 million in the US market.
Comments
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.